Find your path to Dipal
105 people in our graph share verified history with Dipal — schools, employers, funds. One of them is your warm intro.
Todd FoleyunlockedDipal: together at Entrada Therapeutics, Inc.
×5Dipal: together at Publicis Sapient
Dipal: together at Catalent
×2Dipal: together at Entrada Therapeutics, Inc.
About
Dipal Doshi is Chief Executive Officer and a board member of Entrada Therapeutics (NASDAQ: TRDA), a clinical-stage biopharmaceutical company he joined as its first full-time employee in 2017. He has nearly 30 years of experience in the life sciences industry and previously served as Chief Business Officer at Amicus Therapeutics, along with senior roles at a healthcare private equity fund and Catalent. Doshi holds an MBA from The Wharton School of the University of Pennsylvania and a BA in English and Political Science from Rutgers University, and serves on the boards of the Biotechnology Innovation Organization, Azenta Life Sciences (NASDAQ: AZTA), and āshibio.
Chief Executive Officer at Entrada Therapeutics, Inc.
Intro paths
→
In turn, Dipal can intro founders to Entrada Therapeutics, Inc.'s investors below.
Experience
- Entrada TherapeuticsChief Executive Officer & Board Membercurrent2017 — presentBoston, Massachusetts, United States
- Biotechnology Innovation OrganizationMember, Board of Directorscurrent2026 — present
- Azenta Life SciencesMember, Board of Directorscurrent2025 — present
- āshibio, IncMember, Board of Directorscurrent2024 — present
- Amicus TherapeuticsChief Business Officer2014 — 2017Cranbury, New Jersey, United States
- Auven TherapeuticsSenior Vice President, Investments & Business Development2008 — 2013New York, New York, United States
- Catalent Pharma SolutionsHead, Corporate Development | Interim General Management Roles2005 — 2008Somerset, New Jersey, United States
- Merrill LynchAssociate, Investment Banking Group2004 — 2005New York, New York, United States
- Eli Lilly and CompanyHead, Oncology Healthcare Services for Lilly Ventures | Senior Associate, Oncology Marketing Group2001 — 2003Indianapolis, Indiana, United States
- Publicis SapientEngagement Manager, Strategy & Program Management Consulting Practices1998 — 2000Chicago, Illinois, United States
- Eli Lilly and CompanyPharmaceutical Sales Representative1997 — 1998New York, New York, United States
Skills & more
Executive LeadershipBoard of DirectorsBiotechnologyResearch and Development (R&D)Business DevelopmentBusiness StrategyHealthcareBiopharmaceuticalsBiotechnology IndustryPharmaceutical IndustryGeneral ManagementCorporate Leadership
+12 more
Corporate StrategyStrategic PartnershipsStrategic LeadershipInvestor RelationsOrganizational DevelopmentCorporate DevelopmentDrug DevelopmentClinical DevelopmentProduct DevelopmentRare DiseasesStrategic PlanningStrategyFrom Dipal's professional profile.
Frequently asked questions
- Who is Dipal Doshi?
- Dipal Doshi is Chief Executive Officer and a board member of Entrada Therapeutics (NASDAQ: TRDA), a clinical-stage biopharmaceutical company he joined as its first full-time employee in 2017. He has nearly 30 years of experience in the life sciences industry and previously served as Chief Business Officer at Amicus Therapeutics, along with senior roles at a healthcare private equity fund and Catalent. Doshi holds an MBA from The Wharton School of the University of Pennsylvania and a BA in English and Political Science from Rutgers University, and serves on the boards of the Biotechnology Innovation Organization, Azenta Life Sciences (NASDAQ: AZTA), and āshibio.
- Where does Dipal Doshi work?
- Dipal Doshi is Chief Executive Officer at Entrada Therapeutics, Inc..
- Where did Dipal Doshi go to school?
- Dipal Doshi studied at The Wharton School (Master of Business Administration (MBA)); Rutgers University (Bachelor of Arts, English and Political Science).
Same school
Also attended The Wharton School2,000
Sarah GuoFounder & General Partner of ConvictionJosh KopelmanFounder and Partner at First Round CapitalAydin SenkutFounder & Managing Partner at FelicisJack AbrahamFounder, CEO & Managing Partner of AtomicKatie RiesterPartner, Head of Investor Relations at Felicis VenturesTrevor OelschigInvestment Team at General Catalyst
+ 1,994 more
Also attended Rutgers University306
Jigar RaythathaInvestor at Third Rock VenturesRobin LiInvestor at GGV CapitalDominique LittleGovernment Affairs Lead at ParadigmGanesh PersadVice President & Chief Information Officer at Flare Capital PartnersBill DeJianneSales Manager (Eastern U.S.) at Needham FundsMark FieldsInvestor at Alsop Louie Partners
+ 300 more
Shared employers
Also worked at Biotechnology Innovation Organization33
Nessan BerminghamInvestor at Khosla VenturesTara SullivanPrincipal at Flare Capital PartnersJessica SagersCommunications Inquiries Contact at Deerfield Management CompanyJohn MaraganoreAdvisor at Oak HC/FTJohn GlasspoolVenture Partner at Agent CapitalThomas NagyOperational Partner at Astanor Ventures
+ 27 more
Also worked at Auven Therapeutics1
Also worked at Catalent Pharma Solutions14
Jay FraserInvestor at Side Door VenturesBrad MorieSenior Director, Biotechnologies at Research Corporation TechnologiesOtello StampacchiaManaging Director at Omega FundsPatrick StragierInvestment Manager at Meusinvest (Noshaq)Oly UgorjiAnalyst at Blueprint EquityRussell BeckermanFounder / EIR at 82VS
+ 8 more
Also worked at Merrill Lynch857
Hans TungManaging Partner at Notable CapitalAnthony LinHead of Intel Capital, Corporate Vice President at Intel CapitalNoorPartner at Clear VenturesKesha CashFounder & General Partner at Impact America FundAftab MathurManaging Director at Temasek at Golden Gate VenturesAndrew WallaceVice President, Revolution Growth at Revolution
+ 851 more